Renal cytochrome P450-derived eicosanoids and hypertension

Current Hypertension Reviews

Volumn 2, Issue 3, 2006, Pages 227-236

  Wang, Mong Heng ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

20 HETE; Cytochrome P450; DHET; EET; Eicosanoids; Hypertension; Kidney; Renal function

Indexed keywords

1 AMINOBENZOTRIAZOLE; 10 UNDECYNYLSULFATE; 12,12 DIBROMODODEC 11 ENOIC ACID; 17 OCTADECYNOIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 (2 PROPARGYLOXYPHENYL)HEXANOIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTISENSE OLIGODEOXYNUCLEOTIDE; ARACHIDONIC ACID; CALCIUM ACTIVATED POTASSIUM CHANNEL; CYTOCHROME B5; CYTOCHROME P450; CYTOCHROME P450 2C11; CYTOCHROME P450 2C9; CYTOCHROME P450 4A; CYTOCHROME P450 4A1; CYTOCHROME P450 INHIBITOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; FIBRIC ACID DERIVATIVE; FUROSEMIDE; HET 0016; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; N HYDROXY N' (4 BUTYL 2 METHYLPHENYL)FORMAMIDINE; N METHYLSULFONYL 12,12 DIBROMODODEC 11 ENAMIDE; N METHYLSULFONYL 15,15 DIBROMOPENTADEC 14 ENAMIDE; N METHYLSULFONYL 6 (2 PROPARGYLOXYPHENYL)HEXANAMIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ARACHIDONIC ACID METABOLISM; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; DRUG POTENCY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SPECIFICITY; ESSENTIAL HYPERTENSION; GENE EXPRESSION; HUMAN; HYPERTENSION; IC 50; ICOSANOID METABOLISM; KIDNEY TUBULE; KIDNEY TUBULE EPITHELIUM; MATERNAL HYPERTENSION; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR;

EID: 33748114969     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340206778132608     Document Type: Review

References (110)

1. Simpson AE. The cytochrome P450 4 (CYP4) family. Gen Pharmacol 1997; 28:351-359.
2. Laniado-Schwartzman M, Abraham NG. The renal cytochrome P450 arachidonic acid system. Pediat Nephrol 1992; 6:490-498.
3. White RE. The involvement of free radicals in the mechanisms of monooxygenases. Pharmacol Ther 1991; 49:21-42.
4. Scott EE, He YA, Wester MR, et al. An open conformation of mammalian cytochrome P450 2B4 at 1.6-A resolution. Proc Natl Acad Sci USA 2003; 100: 13196-13201.
5. Poulos TL. The past and present of P450cam structural biology. Biochem Biophys Res Commun 2003; 312:35-39.
6. Taniguchi H, Imai Y, Sato R. Role of the electron transfer system in microsomal drug monooxygenase reaction catalyzed by cytochrome P-450. Arch Biochem Biophys 1984; 232:585-596.
7. Strobel HW, Fang WF, Takazawa RS, et al. Cytochrome P450 and the activation and inactivation of mutagens and carcinogens. Basic Life Sci 1986; 39:61-71.
8. Nadler SG, Strobel HW. Identification and characterization of an NADPH-cytochrome P450 reductase derived peptide involved in binding to cytochrorne P450. Arch Biochem Biophys 1991; 290:277-284.
9. Black SD, Coon MJ. P450 cytochromes: structure and function. Adv Enzymol Relat Areas Mol Biol 1987; 60:35-87.
10. Roman RJ. P450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82:131-185.
11. Claire AE, Simpson M. The cytochrome P450 4 (CYP4) family. Gen Pharmac 1997; 28:351-359.
12. Okita RT, Okita JR. Cytochrome P450 4A fatty acid omega hydroxylases. Curr Drug Metab 2001; 2:265-281.
13. D.N.Muller, E. Barbosa-Sicard, C. Schmidt, M. Markovic, F.C. Luft, W.H. Schunck. Gender- and strain-specific expression of Cyp4a isoforms and their role in mouse renal 20-HETE production. Hypertension 2004; 44, P176.
14. Nguyen X, Wang MH, Reddy KM, Falck JR, Schwartzman ML. Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol 1999; 276:R1691-R1700.
15. Ito O, Alonso-galicia M, Hopp KA, Roman RJ. Localization of cytochrome P450 4A isoforms along the rat nephron. Am J Physiol 1998; 274:F395-F404.
16. Marji J, Wang H-M, Schwartzman M. Cytochrome P450 isoform expression and 20-hydroxyeicosatetraenoic acid synthesis in renal preglomerular arteries. Am J Physiol 2002; 283:F60-F67.
17. Imaoka S, Yamazoe Y, Kato I, Funae Y. Hormonal regulation of rat cytochrome P450s by androgen and pituitary. Arch Biochem Biophys 1992; 299:179-184.
18. Nakagawa K, Marji JS, Schwartzman ML, Waterman MR, Capdevila JH. The androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension. Am J Physiol 2003; 284: R1055-R1062.
19. Hoch U, Falck JR, de Montellano PR. Molecular basis for the omega-regiospecificity of the CYP4A2 and CYP4A3 fatty acid hydroxylases. J Biol Chem 2000; 275:26952-26958.
20. Cowart LA, Wei S, Hsu MH, et al. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J Biol Chem 2002; 277: 35105-35112.
21. Wang MH, Guan H, Nguyen X, Zand BA, Nasjletti A, Laniado-Schwartzman M. Contribution of cytochrome P450 4A1 and 4A2 to vascular 20- hydroxyeicosatetraenoic acid synthesis in rat kidneys. Am J Physiol 1999; 276:F246-F253.
22. Xu F, Falck JR, Ortiz de Montellano PR, Kroetz DL. Catalytic activity and isoform-specific inhibition of rat cytochrome P450 4F enzymes. J Pharmacol Exp Ther 2004; 308:887-895.
23. Chen L, Hardwick JP. Identification of a new P450 subfamily, CYP4F1, expressed in rat hepatic tumors. Arch Biochem Biophys 1993; 300:18-23.
24. Kawashima H, Kusunose E, Thompson CM, Strobel HW. Protein expression, characterization, and regulation of CYP4F4 and CYP4F5 cloned from rat brain. Arch Biochem Biophys 1997; 347:148-154.
25. Kalsotra A, Anakk S, Boehme CL, Strobel HW. Sexual dimorphism and tissue specificity in the expression of CYP4F forms in Sprague Dawley rats. Drug Metab Dispos 2002; 30:1022-1028.
26. Wang M-H, Brand-Schieber E, Zand BA, et al. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: Characterization of selective inhibitors. J Pharmacol Exp Ther 1998; 284:966-973.
27. Capdevila JH, Shouzou W, Yan J, et al. Cytochrome P450 arachidonic acid epoxygenase:Regulatory control of the renal epoxygenase by dietary salt loading. J Biol Chem 1992; 267:21720-21726.
28. Oliw EH. Oxygenation of polyunsaturated fatty acids by cytochrome P450 monooxygenases. Prog Lipid Res 1994; 33:329-354.
29. Karara A, Makita K, Jacobson HR, et al. Molecular cloning, expression and enzymatic characterization of the rat kidney cytochrome P450 arachidonic acid epoxygenase. J Biol Chem 1993; 268:13565-13570.
30. Holla VR, Makita K, Zaphiropoulos PG, Capdevila JH. The kidney cytochrome P450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest 1999; 104:751-760.
31. Ma J, Qu W, Scarborough PE, et al. Molecular cloning, enzymatic characterization, developmental expression, and cellular locatization of a mouse cytochrome P450 highly expressed in kidney. J Biol Chem 1999; 274:17777-17788.
32. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 1996; 271:3460-3468.
33. Brand-Schieber E, Falck JF, Schwartzman M. Selective inhibition of arachidonic acid epoxidation in vivo. J Physiol Pharmacol 2000; 51:655-672.
34. Ogungbade GO, Akinsanmi LA, Jiang H, Oyekan AO. Role of epoxyeicosatrienoic acids in renal functional response to inhibition of NO production in the rat. Am J Physiol 2003; 285:F955-F964.
35. Zhou Y, Chang HH, Du J, Wang CY, Dong Z, Wang MH. Renal epoxyeicosatrienoic acid synthesis during pregnancy. Am J Physiol 2005; 288:F221-F226.
36. Imig JD, Falck JR, Wei S, Capdevila JH. Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. J Vasc Res 2001; 38:247-255.
37. Cheng MK, Doumad AB, Jiang H, Falck JR, McGiff JC, Carroll MA. Epoxyeicosatrienoic acids mediate adenosine-induced vasodilation in rat preglomerular microvessels (PGMV) via A2A receptors. Br J Pharmacol 2004; 141:441-448.
38. Miyata N, Taniguchi K, Scki T, et al. HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J. Pharmacol 2001; 133:325-329.
39. Xu F, Straub WO, Pak W, et al. Antihypertensive effect of mechanism-based inhibition of renal arachidonic acid omega-hydroxylase activity. Am J Physiol 2002; 283:R710-R720.
40. Kehl F, Cambj-Sapunar L, Maier KG, et al. 20-HETE contributes to the acute fall in cerebral blood flow after subarachnoid hemorrhage in the rat. Am J Physiol 2002; 282:H1556-H1565.
41. Alonso-galicia M, Maier KG, Greene AS, Cowley AW, Jr., Roman RJ. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am J Physiol 2002; 283:R60-R68.
42. Kroetz DL, Xu F. Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol 2005; 45:413-438.
43. Su P, Kaushal KM, Kroetz DL. Inhibition of renal arachidonic acid omega-hydroxylase activity with ABT reduces blood pressure in the SHR. Am J Physiol 1998; 275:R426-R438.
44. Wang MH, Zand BA, Nasjletti A, Laniado-Schwartzman M. Renal 20-hydroxyeicosatetraenoic acid synthesis during pregnancy. Am J Physiol 2002; 282:R383-R389.
45. Dos Santos EA, Dahly-Vernon AJ, Hoagland KM, Roman RJ. Inhibition of the formation of EETs and 20-HETE with 1-aminobenzotriazole attenuates pressure natriuresis. Am J Physiol 2004; 287:R58-R68.
46. Hoagland KM, Flasch AK, Roman RJ. Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 2003; 42:669-673.
47. Zou A-P, Ma Y-H, Sui Z-H, et al. Effect of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochromc P450 fatty acid ω-hydroxylase, on renal function. J Pharmacol Exp Ther 1994; 268:474-481.
48. Wang MH, Zhang F, Marji J, Zand BA, Nasjletti A, Laniado-Schwartzman M. CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. Am J Physiol 2001; 280:R255-R261.
49. Hercule HC, Wang MH, Oyekan AO. Contribution of cytochrome P450 4A isoforms to renal functional response to inhibition of nitric oxide production in the rat. J Physiol 2003; 551:971-979.
50. Fleming I. Cytochrome P450 and vascular homeostasis. Circ Res 2001; 89:753-762.
51. Medhora M, Daniels J, Mundey K, et al. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol 2003; 284:H215-H224.
52. Omata K, Abraham NG, Laniado-Schwartzman M. Arachidonic acid ω/ ω-l hydroxylase along the nephron of the spontaneously hypertensive rat. Am J Physiol 1992; 262:F592-599.
53. Lin F, Rios A, Falck JR, Belosludtsev Y, Laniado Schwartzman M. 20-Hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. Am J Physiol 1995; 269:F806-F816.
54. +-ATPase through a cytochrome P450 pathway. Am J Physiol 1994; 266:F497-F505.
55. +-ATPase. J Clin Invest 1997; 99:1224-1230.
56. Quigley R, Baum M, Reddy KM, Griener JC, Falck JR. Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. Am J Physiol 2000; 278:F949-F953.
57. Escalante B, Erlij D, Falck JR, McGiff JC. Cytochrome P450 arachidonate metabolites affect ion fluxes in rabbit medullary thick ascending limb. Am J Physiol 1994; 266:C1775-C1782.
58. Escalante B, Falck JR, Yadagiri P, Sun L, Schwartzman M. 19(S)-hydroxyeicosatetraenoic acid is a potent stimulator of renal Na,K-ATPase. Biochem Biophys Res Commun 1988; 152:1259-1274.
59. + channel in the thick ascending limb of the rat kidney. J Gen Physiol 1995; 106:727-743.
60. Satoh T, Cohen HT, Katz AI. Intracellular signaling in the regulation of Na-K-ATPase: II. Role of eicosanoids. J Clin Invest 1993; 91:409-415.
61. McGiff JC, Quilley J. 20-HETE and the kidney: resolution of old problems and new beginnings. Am J Physiol 1999; 277:R607-R623.
62. Imig JD. Eicosanoid regulation of the renal vasculature. Am J Physiol 2000; 279:F965-F981.
63. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 1996; 7:2364-2370.
64. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996; 78:415-423.
65. Imig JD, Falck JR, Inscho EW. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Br J Pharmacol 1999; 127:1399-1405.
66. Imig JD, Zou A-P, Ortiz-de-Montellano PR, Sui Z, Roman RJ. Cytochrome P450 inhibitors alter afferent arteriolar responses to elevations in pressure. Am J Physiol 1994; 266:H1879-H1885.
67. Kauser K, Clark JE, Masters BS, et al. Inhibitors of cytochrome P450 attenuate the myogenic response of dog renal arcuate arteries. Circ Res 1991; 68:1154-1163.
68. White SM, Imig JD, Kim TT, Hauschild BC, Inscho EW. Calcium signaling pathways utilized by P2X receptors in freshly isolated preglomerular MVSMC. Am J Physiol 2001; 280:F1054-F1061.
69. Zhao X, Falck JR, Gopal VR, Inscho EW, Imig JD. P2X Receptor-stimulated calcium responses in preglomerular vascular smooth muscle cells involves 20-hydroxyeicosatetraenoic acid. J Pharmacol Exp Ther 2004; 311:1211-1217.
70. Hercule H, Oyekan A. Renal cytochrome P450 oxygenases and preglomerular vascular response to arachidonic acid and endothelin-I following ischemia/reperfusion. J Pharmacol Exp Ther 2002; 302:717-724.
71. + channel activity and vascular tone in renal arterioles. Circ Res 1998; 83:1069-1079.
72. + channel in renal arterioles. Am J Physiol 1996; 270:R228-R237.
73. Zou A-P, Imig JD, Ortiz de Montellano PR, Sui Z, Falck JR, Roman RJ. Effect of P450 ω-hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. Am J Physiol 1994; 266:F934-F941.
74. Sacerdoti D, Escalante B, Abraham NG, McGiff JC, Levere RD, Schwartzman ML. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science 1989; 243:388-390.
75. DaSilva J-L, Tiefenthaler M, Park E, Escalante B, Schwartzman ML, Abraham NG. Tin mediated heme oxygenase gene activation and cytochrome P450 arachidonate hydroxylase inhibition in spontaneously hypertensive rats. Am J Med Sci 1994; 70:173-181.
76. Escalante B, Sacerdoti D, Davidian MM, Schwartzman ML, McGiff JC. Chronic treatment with tin normalizes blood pressure in spontaneoulsy hypertensive rats. Hypertension 1991; 17:776-779.
77. Muthalif MM, Benter IF, Khandekar Z, et al. Contribution of ras GTPase/ MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension. Hypertension 2000; 35: 457-463.
78. Muthalif MM, Karzoun NA, Gaber L, et al. Angiotensin II-induced hypertension: contribution of ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension 2000; 36:604-609.
79. Zou AP, Drummond HA, Roman RJ. Role of 20-HETE in elevating loop chloride reabsorption in Dahl SS/Jr rats. Hypertension 1996; 27:631-635.
80. Stec DE, Mattson DL, Roman RJ. Inhibition of renal outer medullary 20-HETE production produces hypertension in Lewis rats. Hypertension 1997; 29:315-319.
81. Roman RJ, Ma Y-H, Frohlich B, Markham B. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 1993; 21:985-988.
82. Stec DE, Deng AY, Rapp JP, Roman RJ. Cytochrome P4504A genotype cosegregates with hypertension in Dahl S rats. Hypertension 1996; 27:564-568.
83. Stec DE, Trolleit MR, Krieger JE, Jacob HJ, Roman RJ. Cytochrome P4504A activity and salt sensitivity in spontaneously hypertensive rats. Hypertension 1996; 27:1329-1336.
84. Imig JD, Falck JR, Roman RJ. 20-hydroxyeicosatetraenoic acid (20-HETE) is a potent endogenous vasoconstrictor of renal arterioles. FASEB J 1993; 7:A888.
85. Makita K, Takahashi K, Karara A, Jacobson HR, Falck JR, Capdevila JH. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induced hypertension in rats fed a high salt diet. J Clin Invest 1994; 94:2414-2420.
86. Roman RJ, Maier KG, Sun CW, Harder DR, Alonso-galicia M. Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol 2000; 27:855-865.
87. Yu Z, Xu F, Huse LM, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000; 87:992-998.
88. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 2000; 275:40504-40510.
89. Lindheimer MD, Katz AI. In: Seldin DW, Giebisch G Eds, The Kidney: Physiology and Pathophysiology. New York, Raven Press, 1992; 3371-3431.
90. Alexander BT, Miller MT, Kassab S, et al. Differential expression of renal nitric oxide synthase isoforms during pregnancy in rats. Hypertension 1999; 33:435-439.
91. Khalil RA, Granger JP. Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. Am J Physiol 2002; 283:R29-R45.
92. Wang MH, Wang J, Chang HH, et al. Regulation of renal CYP4A expression and 20-HETE synthesis by nitric oxide in pregnant rats. Am J Physiol 2003; 285:F295-F302.
93. Llinas MT, Alexander BT, Capparelli MF, Carroll MA, Granger JP. Cytochrome P450 inhibition attenuates hypertension induced by reductions in uterine perfusion pressure in pregnant rats. Hypertension 2004; 43:623-628.
94. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41:625-633.
95. Dobrian AD, Davies MJ, Prewitt RL, Lauterio TJ. Development of hypertension in a rat model of diet-induced obesity. Hypertension 2000; 35:1009-1015.
96. Wang MH, Smith A, Zhou Y, et al. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension 2003; 42:594-599.
97. Zhou Y, Lin S, Chang HH, et al. Gender differences of renal CYP-derived eicosanoid synthesis in rats fed a high-fat diet. Am J Hypertens 2005; 18:530-537.
98. Zhao X, Dey A, Romanko OP, et al. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol 2005; 288:R188-R196.
99. Ma YH, Schwartzman ML, Roman RJ. Altered renal P450 metabolism of arachidonic acid in Dahl salt- sensitive rats. Am J Physiol 1994; 267:R579-R589.
100. Roman RJ, Ma YH, Frohlich B, Markham B. Clofibrate prevents the development of hypertension in Dahl salt- sensitive rats. Hypertension 1993; 21:985-988.
101. Laffer CL, Laniado-Schwartzman M, Wang MH, Nasjletti A, Elijovich F. Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic Acid in human salt-sensitive versus salt-resistant hypertension. Circulation 2003; 107:574-578.
102. Laffer CL, Laniado-Schwartzman M, Nasjletti A, Elijovich F. 20-HETE and circulating insulin in essential hypertension with obesity. Hypertension 2004; 43:388-392.
103. Sacerdoti D, Balazy M, Angeli P, Gatta A, McGiff JC. Eicosanoid excretion in hepatic cirrhosis: predominance of 20-HETE. J Clin Invest 1997; 100:1264-1270.
104. Ward NC, Rivera J, Hodgson J, et al. Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 2004; 110:438-443.
105. Catella F, Lawson JA, Fitzgerald DJ, FitzGerald GA. Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci U S A 1990; 87:5893-5897.
106. Chen G, Cheung DW. Modulation of endothelium-dependent hyperpolarization and relaxation to acetylcholine in rat mesenteric artery by cytochrome P450 enzyme activity. Circ Res 1996; 79(4): 827-833.
107. Fisslhaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999; 401:493-497.
108. Fleming I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol Res 2004; 49:525-533.
109. Halcox JP, Narayanan S, Cramer-Joyce L, Mincemoyer R, Quyyumi AA. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am J Physiol 2001; 280: H2470-H2477.
110. Versara D, Cipriano A, Virdis A, S et al. Involvement of cytochrome P450 2C9 pathway sensitive to sulfaphenazole in the endothelium-dependent vasodilation of essential hypertensive patients. Hypertension 2004; 44, P131.